Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and Health
Here, researchers report on their investigation of gene therapy to introduce a bacterial enzyme, lipoic acid protein ligase A (LplA), into mammals in order to improve mitochondrial metabolism. LplA undertakes lipoylation of proteins, attaching lipoic acid to the protein, and does so somewhat more efficiently than the analogous enzymes in mammals. Lipoylation is known to be involved in the regulation of metabolism, and is largely researched in the context of conditions exhibiting lipoylation deficiency. Here, however, the focus is on enhancement of metabolism in healthy individuals over the course of aging. This is interesting work, but at the present time it would be very hard to convince investors to fund and regulators to approve the introduction of a bacterial protein into humans as a basis for therapy; there is a strong assumption that a negative immune reaction would result, and a consequently high bar set for proof that it doesn't.
As primary energy producers, mitochondria generate adenosine 5′-triphosphate (ATP) through efficient oxidative phosphorylation, but this process inevitably produces reactive oxygen species (ROS), which act as crucial signaling mediators at physiological levels yet become drivers of cellular aging and functional decline when accumulated excessively. Thus, an essential challenge involves maintaining an optimal balance between energy production and ROS management to achieve truly efficient and clean energy metabolism. This biochemical context raises the core question of whether interventions can be developed that enhance energy metabolism while simultaneously minimizing oxidative damage, thereby combining the benefits of both vitality and longevity.
Lipoylation is an essential posttranslational modification that directly influence the enzyme activity, and its substrates including enzymes serve as strategic metabolic gatekeepers. In higher eukaryotes, lipoylation is sequentially coordinated by multiple enzymes, whereas in Escherichia coli, a single enzyme, LplA, is sufficient to complete the entire process with remarkable efficiency. Our recent studies demonstrated that this bacterial enzyme not only rescues lipoylation deficiencies but also functions as a metabolic enhancer that significantly boosts energy production.
We conducted cross-species expression studies in Caenorhabditis elegans and mouse models and comprehensive physiological assessments across their life stages. The results demonstrate that this enzymatic intervention effectively enhances lipoylation and energy metabolism while lowering ROS level. The favorable metabolic state translates to broad physiological benefits, including enhanced motility and stress resistance in early life, and delayed age-related decline with extended health span when intervention begins later in life.